Weesp, Netherlands

Andrew C McCreary


Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 24(Granted Patents)


Location History:

  • Weesp, NL (2004 - 2012)
  • Weep, NL (2012)

Company Filing History:


Years Active: 2004-2012

Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Andrew C McCreary

Introduction

Andrew C McCreary is a notable inventor based in Weesp, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for disorders related to dopaminergic function. With a total of 11 patents to his name, McCreary's work has had a profound impact on medical science.

Latest Patents

Among his latest patents is a composition that combines bifeprunox and a dopamine agonist. This invention is aimed at treating disorders that require recovery of dopaminergic function, including Parkinson's disease and restless leg syndrome. Another notable patent involves a group of novel phenylpiperazine derivatives that exhibit a dual mode of action, including serotonin reuptake inhibition and partial agonism on dopamine-D receptors. These compounds are designed for the manufacture of medicaments that provide beneficial effects.

Career Highlights

Throughout his career, McCreary has worked with prominent companies in the pharmaceutical industry, including Solvay Pharmaceuticals B.V. and Solvay Pharmaceuticals GmbH. His expertise in drug development and innovation has positioned him as a key figure in his field.

Collaborations

McCreary has collaborated with esteemed colleagues such as Gustaaf J M Van Scharrenburg and Cornelis G Kruse. These partnerships have further enhanced his research and development efforts.

Conclusion

Andrew C McCreary's contributions to pharmaceutical innovation are noteworthy, particularly in the treatment of neurological disorders. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…